Invivyd reports PEMGARDA neutralizes dominant SARS-CoV-2 variant LP.8.1

Invivyd, Inc.

New in vitro data show PEMGARDA (pemivibart) neutralizes dominant LP.8.1 variant, consistent with prior variants.
CDC reports LP.8.1, XEC, and KP.3.1.1 make up majority of U.S. cases; all susceptible to PEMGARDA.
Pemivibart activity remains within expected assay variability range since Omicron BA.2.
Data provided to U.S. FDA; update to PEMGARDA Fact Sheet for Healthcare Providers anticipated.
VYD2311, next-gen mAb candidate, also demonstrates neutralizing activity against LP.8.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.